A conversation with Dr. Jeremie Calais, assistant professor of UCLA's Molecular and Medical Pharmacology department and IUO researcher, during the Prostate Cancer Foundation's 25th Annual Scientific Retreat regarding the "Effectiveness and Resistance to PSMA targeted RadioLigand Therapy using 177 Lu-PSMA-617."
Video on urotoday.com >
UCLA researcher uses big data to help optimize cancer treatment. How can datasets help reveal new ways to treat cancer? UCLA Jonsson Cancer Center's Paul Boutros shares how his lab is working in collaboration with research centers around the world to use big data to help develop new ways to fight this disease.
Story on newsroom.ucla.edu >
Aggressive Systemic and Multi-Modal Therapy to Treat Metastatic Kidney Cancer
UCLA oncologist Sandy Liu, MD, talked about UCLA’s multi-disciplinary treatment approach to target advanced kidney cancer. The team approaches each case individually with the hope of eradicating all disease with aggressive systemic therapy and, when feasible, adding multi-modal therapy to consolidate residual disease. View the webinar >
Amar U. Kishan, MD, UCLA IUO researcher and radiation oncologist, was the lead author on a new UCLA-led study showing that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment. UCLA Newsroom >
Targeted Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of metastatic castration-resistant prostate cancer. View Clinical Trial >
Artificial Intelligence Performs as Well as Experienced Radiologists in Detecting Prostate Cancer - Left: Ruiming Cao, Dr. Steven Raman & Kyung Sun. Researchers compared the system’s results with readings by UCLA doctors who had more than 10 years of experience. UCLA Newsroom >